Substitute for Raised S.B. No. 262
Session Year 2021
AN ACT REQUIRING MANUFACTURERS OF BRAND NAME PRESCRIPTION DRUGS TO PROVIDE SAMPLES OF SUCH DRUGS TO MANUFACTURERS OF GENERIC PRESCRIPTION DRUGS.
To promote competition in the prescription drug market by allowing developers of generic drugs and biosimilar products to obtain reference samples.